Pharmacogenetic profile and major depressive and/or bipolar disorder treatment: a retrospective, cross-sectional study.

Tonozzi TR1, Braunstein GD1, Kammesheidt A1, Curran C2, Golshan S3, Kelsoe J3.

Author information

Abstract

AIM:

To compare pharmacogenetic test predictions with self-reported treatment experience and side effect tolerability among patients with depression taking psychotherapeutic medications.

METHODS:

Subjects completed a survey recalling medication effectiveness and side effects and then underwent pharmacogenetic testing.

RESULTS:

Our 15 gene pharmacogenetic panel predicted efficacy (p < 0.001) but did not predict side effect tolerability (p = 0.70) in a group of 352 patients. The pharmacogenetic panel and reported efficacy corresponded 60% of the time and medication tolerability agreed 71% of the time.

CONCLUSION:

Pharmacogenetic testing may be a useful adjunct to predict efficacy of medications used to treat depression.

KEYWORDS:

antidepressant; antipsychotic; bipolar disorder; generalized anxiety disorder; major depressive disorder; mood stabilizer; pharmacogenetics; selective serotonin reuptake inhibitors; tricyclic antidepressants